<DOC>
	<DOC>NCT00403754</DOC>
	<brief_summary>This study was designed to provide data about the safety and efficacy of 3 doses of indacaterol (150, 300, and 600 µg) in Japanese asthma patients so that an optimal dose, or doses, could be chosen for testing in later studies.</brief_summary>
	<brief_title>Dose Ranging Study for Indacaterol in Japanese Asthma Patients</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Male and female Japanese asthmatic patients aged 18 to 75 years old. Patients who have been hospitalized or had emergency room treatment for an acute asthma attack in the 6 months prior to the first day of screening or during the screening period. Patients who have used tobacco products within 6 months prior to the first day of screening or have a smoking history of greater than 10 pack years. Patients with a history of malignancy with the exception of localized basal cell carcinoma of the skin. Pregnant or nursing (lactating) women. Patients who have had treatment with disallowed medications including investigational drug. Other protocoldefined inclusion/exclusion criteria applied to the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>asthma</keyword>
	<keyword>QAB149</keyword>
	<keyword>indacaterol</keyword>
	<keyword>long acting β2-agonist</keyword>
	<keyword>bronchodilator</keyword>
</DOC>